

2012 Letter to FDA regarding Gadolinium Toxicity from GBCAs

On October 23, 2012, our efforts to bring attention to the issue of gadolinium retention in patients with normal renal function began with a letter I wrote to the FDA. Because of the significance of that letter and its relevance to our ongoing work in patient advocacy, education, and research, I have decided to make it available to the public by posting a PDF of it on www.GadoliniumToxicity.com.

The purpose of my letter was twofold. First, I wanted to bring attention to the health problems that patients with normal renal function were experiencing after administration of a Gadolinium-based Contrast Agent. Second, I hoped to bring about a realization of the serious health threat that GBCAs might pose to potentially all patient populations including patients with normal renal function. (Note: The individual Patient Accounts mentioned in the letter are not included in the PDF.)

When I wrote the letter, the only gadolinium-related problem recognized by the FDA and medical community was Nephrogenic Systemic Fibrosis (NSF), and it was widely published that it only occurred in people with severely impaired renal function. Patients with an estimated glomerular filtration rate greater than 60 (eGFR >60) were routinely told they would not retain gadolinium. Despite urine test results which showed elevated levels of gadolinium months and even years after their contrast procedures, people with normal renal function continued to be told that their unexplained symptoms could not be caused by the gadolinium-based contrast agent they had received for their MRI.

My research of the literature published prior to 2012 seemed to indicate otherwise, and I believe that more recently published studies have confirmed my concerns and those expressed by other affected patients. Published evidence of gadolinium retention in patients and animals with normal renal function has existed for quite some time. The toxic effects of gadolinium are also well-documented.

I have been in periodic contact with someone at the FDA since early 2013. Though I believe that the FDA seriously considered my letter, it took until July 27, 2015 to issue its first Safety Announcement regarding gadolinium retention in patients with normal renal function. Research is ongoing; however, in my opinion, it is moving much too slowly all while patients continue to be adversely affected. As I stated in my letter, "I believe the already published scientific data related to Gadolinium-Based Contrast Agents and the toxic effects of free Gadolinium call into serious question the long-term safety of using these contrast agents in all patient populations. Based on the totality of the facts, I believe immediate action by the FDA is warranted." I said that in 2012, and I believe that even more strongly now in 2016.

My letter to FDA Commissioner Margaret A. Hamburg, M.D., dated 10/23/2012, is copyrighted material and my intellectual property. Proper credit should be given when reposting or sharing all or any part of my letter on any print or electronic media.

Due to privacy and security concerns, my phone number and address have been removed. Anyone wishing to speak to me should contact me via email at Sharon@GadoliniumToxicity.com.

Sharon Williams
10/28/2016

www.GadoliniumToxicity.com

© 2012-2016 Sharon Williams. All Rights Reserved.

###

October 23, 2012

Commissioner Margaret A. Hamburg, M.D.
U.S. Food and Drug Administration
10903 New Hampshire Avenue
WO Bldg. 1, Room 2217
Silver Springs, MD 20993

Re: Gadolinium Toxicity from GBCAs

Dear Dr. Hamburg:

My name is Sharon Williams. I am writing to you about Gadolinium-Based Contrast Agents, which I believe may be placing millions of people at serious risk of irreparable harm. I have come to this conclusion after researching Gadolinium-related articles in order to try to make some sense of my own medical situation. My research has led me to believe that I am a victim of Gadolinium Toxicity caused by the Gadolinium-Based Contrast Agent I received for MRIs. I had 5 MRIs with Magnevist (Gd-DTPA) with a cumulative dose of 90 cc. Since April 6, 2010, 18 days after my 5th MRI with Magnevist, I have suffered from several unresolved and as yet still unexplained health issues. However, this letter is by no means meant to be just another adverse event report about a single patient. This is about a far more complicated and serious situation that has the potential to adversely impact countless others both here in the U.S. and around the world.

Because this situation is so important, I hope you will take the time to consider everything that I have to say before reaching any conclusions. I believe you will find my comments well-reasoned and fact-based.

I have spent more than two years doing extensive research into the problems associated with Gadolinium-Based Contrast Agents (GBCAs). All of my research has been taken from published research studies and articles; nothing I say is based on biased reporting from blogs, message boards or attorney web sites. Despite all my research, I do not for one moment think that I know more than trained researchers and medical professionals; I definitely know that I don't. However, after reviewing several hundred articles related to Gadolinium-Based Contrast Agents and Gadolinium Toxicity, I believe I can offer intelligent comments that are based on both published scientific facts and logic.

While Gadolinium Toxicity does directly affect me, my overriding motivation is to provide a voice for those who it seems are currently left to fend for themselves in their search for both answers and appropriate medical care. Those with confirmed NSF and the families of deceased NSF patients have an existing community of support; however, those of us with "normal" renal function are still being told that our problems could not possibly be related to our contrast-enhanced MRIs. I believe the published facts indicate otherwise; references are enclosed.

Everything that I'm going to say is based on the fact that Gadolinium (Gd^{3+}) is a toxic Rare Earth Element (REE) and it has no known biological use in the human body.^{1,2} Research using Gadolinium Chloride (free Gd) provides proof of its toxic effects.^{3,4,5,6,7,8,9,10,11,12,13} But because of its paramagnetic properties, it was determined that the Gadolinium ion could be chelated or bound to a ligand so that it could be used as a contrast agent for MRI.^{14,15,16} It was thought this complex would permit the GBCA to move rapidly through the body and then be excreted primarily via the kidneys before the toxic ion and ligand could separate.¹⁴ However, even the report from the initial clinical experience in patients using Gd-DTPA (the first GBCA), warned that "care should obviously be taken in patients with impaired renal and/or hepatic function where high *in vivo* concentrations of Gd-DTPA may occur for prolonged periods".¹⁷ Since at least 1992, dechelation or separation of the ion and ligand due to transmetallation and acid dissociation was confirmed in animal studies.^{18,19,20,21,22} Human *in vivo* comparative studies confirmed transmetallation occurs in *healthy* humans.^{23,24} In addition, the release of Gadolinium from all linear Gd^{3+} complexes in human serum from *healthy* volunteers, was several orders of magnitude greater than predicted by conditional stability constants.²⁵ As you read the rest of my letter, please keep the findings in *healthy* volunteers in mind as I believe these findings provide strong evidence that patients with normal renal function can be adversely affected by the toxic effects of Gadolinium.

Some Background Information: Although it wasn't known at the time, evidence of a problem related to Gadolinium-Based Contrast Agents first appeared in 1997. Because the problem first presented clinically in a group of dialysis patients with severe skin changes and joint contractures, the disease was named Nephrogenic Fibrosing Dermopathy (NFD).^{26,27} Further evaluation including autopsies on deceased NFD patients, found that the damage went far beyond the skin.^{28,29,30} The name was then changed to Nephrogenic Systemic Fibrosis (NSF) to reflect the systemic nature of the disease.³¹ In 2006 the connection was first made between Gadolinium-Based Contrast Agents administered for MRI and the disease currently known as NSF.^{32, 33}

Since 1997, when problems first appeared, much of the focus has been in trying to determine how and why NFD/NSF happened only in renally-impaired patients and although NSF is known to be a systemic disease, the diagnosis seems to still be driven by the skin changes and "visible" evidence of the disease.^{34,35} However, residual Gadolinium from GBCAs has been found in bone and other tissue of study animals that did not have NSF-like skin lesions^{36,37,38,39} and since the free Gadolinium ion is toxic,⁴⁰ it would seem that any amount of Gadolinium that remained in the body would be of concern due to the damage that it is known to cause.

Here is the problem. It appears to me that the FDA and others are proceeding as though NSF and the problems related to Gadolinium-Based Contrast Agents have all but been eradicated^{41,42,43} since the FDA instituted new screening and use guidelines in renally-impaired patients.^{44,45,46} The FDA's own funding opportunity (RFA-FD-12-029)⁴⁷ will employ an existing Quality Assurance (QA) registry of patients with renal failure who received GBCAs as a means to evaluate the effect of Cumulative Dosing. While more will be learned about the effects of Cumulative Dosing of GBCAs, the problems associated with GBCAs go well beyond the narrow community of renally-impaired patients and beyond just the skin manifestations of NSF.

There is a growing body of research that provides evidence of Gadolinium or its toxic effects also being found in bone and tissue of both study animals and humans with *normal renal function*.^{48,49,50,51,52,53,54,55,56} Based on that research, it seems logical to believe that patients with "normal" renal function (meaning eGFR>60) might also be at risk from injected Gadolinium-Based Contrast Agents.

However, now that there are far fewer cases of biopsy-confirmed NSF, it seems that some NSF experts are moving on to other research interests, which is unfortunate since the toxic effects of Gadolinium still exist. Please keep in mind that NSF is not just a skin disease and it is not caused by the kidneys. Dr. Jonathan Kay, Director of Clinical Trials at Massachusetts General Hospital, has suggested that the disease be called Gadolinium-Associated Systemic Fibrosis or GASF, since as he said, "NSF neither originates in the kidney nor is caused by factors originating in the kidney".⁵⁷ It's the Gadolinium in tissue that seems to drive the fibrosis.⁵⁸ This is supported in part by several 2010 studies that found that GBCAs and Gadolinium Chloride stimulate fibroblast proliferation in tissue taken from *healthy* subjects.^{59,60,61} It should be noted that all GBCAs, including macrocyclic GBCAs, were found to stimulate fibroblast proliferation.⁶² Macrocyclic agents are thought to be more stable and thereby safer to use; however, even they have been found to deposit in tissue,^{36,63,64} and there are now confirmed cases of NSF caused by macrocyclic agents as well.⁶⁵

Despite growing evidence that Gadolinium also affects the blood and tissue of those with normal renal function,^{59,60,61,62,66,67,68,69} it appears that no one is looking for more widespread evidence of Gadolinium Toxicity or Gadolinium-Associated Systemic Fibrosis (GASF) in all patients. Or if they are, that information has not yet made its way to the local physicians who are treating patients like me. I have conferred with other patients who despite having "normal" renal function also continue to suffer from unexplained health issues after their exposure to Gadolinium. I have enclosed information provided by 6 such patients; I know others that I feel certain would come forward with their medical records, and I suspect it would take little effort to identify many more. However, since we don't have severe renal impairment (meaning eGFRs <30), most doctors won't even consider that we could be adversely affected by GBCAs, which in turn means that no one is being told about this potential evidence of a more widespread problem related to the use of Gadolinium-Based Contrast Agents in all patients.

I decided that I could wait no longer for someone else to do something, so I made the decision to contact the FDA myself. **I have three requests of the FDA related to Gadolinium Toxicity that I consider equally important; I will provide facts to support each of them.** First, the FDA should take a much broader look at the risks

associated with Gadolinium-Based Contrast Agents beyond just the “visible” skin changes and joint contractures described in NSF-related documents, and it should place more focus on what might be happening on the *inside* of *all* patients, including those with normal renal function. **Second**, the FDA should issue new warnings stating that GBCAs can be harmful to patients with normal renal function, and the FDA should issue warnings about Long-term Cumulative Dose Risk from Multiple Exposures. From what has been learned about NSF and Gadolinium-Based Contrast Agents since 2006, it appears obvious to me that although impaired-renal function is the current marker for NSF, it is not the direct cause of NSF or Gadolinium Toxicity. That being said, it makes sense to me (logically and scientifically) that Gadolinium Toxicity can have an adverse effect on those with normal renal function as well and potentially a long-term negative impact on all (or at least many) that are exposed to Gadolinium. **Third**, the FDA should ensure that *all* groups of patients are included in future research and data gathering, as well as in retrospective studies in order to obtain a true picture of the scope of the problems caused by Gadolinium-Based Contrast Agents. ***If you only look at one specific patient population such as the renally-impaired, for predominantly one specific disease symptom like skin changes, how would you ever expect to know with any certainty whether or not other patient populations are also being harmed by GBCAs?***

What follows will explain the analysis that got me to this point. I have compiled much more additional information, but I have limited this account to what follows because I believe it is so compelling on its own.

After reading several FDA Advisory Committees' Briefing Documents,^{70,71,72,73,74,75,76,77} I realized that no one was looking beyond the “visible” damage currently associated with NSF in the renally-impaired for more widespread evidence of the toxic effects of Gadolinium in all patients that have been exposed to Gadolinium-Based Contrast Agents. Important study findings of Gadolinium being deposited in bone of patients with normal renal function^{78,79} and the instability of linear GBCAs in human serum from healthy volunteers²⁵ appeared to be dismissed simply because they did “not correlate with the relative number of NSF cases reported for the different GBCAs”.⁷² Post-Marketing Requirements were only requested to be done in those patients with moderate to severe renal insufficiency.⁷⁰ To my knowledge, no one is evaluating patients with eGFRs >60. And even within that limited population of renally-impaired patients, NSF is still being diagnosed as though it *only* affects the skin as was first thought in 1997.^{80,81}

Should we only be worried if we can “see” the damage being done by a GBCA, or is it also prudent to be even more concerned about the damage that is out of sight and has the greatest potential to do serious or even fatal harm? Reviews of autopsies performed on deceased NSF patients have identified extensive multiorgan fibrosis and calcification, as well as vascular and extracellular deposits of Gadolinium, including in dura mater and cerebellum.⁸² The damage done goes far beyond what is visible on the skin; the entire body is involved to varying degrees. Autopsies have also shown that Gadolinium can have adverse effects on: liver, lungs, intestinal wall (ileum), kidney, lymph node, skeletal muscle, diaphragm, mitral valve, pleura, subcutaneous tissue, striated muscles, pericardium, aortic arch, great vessels of the heart, cardiac conduction system, left ventricle and septum, blood vessels, atrial myocardium, lesser pelvis, testes, adrenal glands, pancreas, colon, thyroid, gastrointestinal tract including esophagus and stomach, eyes (including blood vessels of choriocapillaris), brain parenchyma, subarachnoid space, dura mater including that surrounding the spinal cord.^{83,84,85,86,87,88,89,90,91,92,93,94,95} *None of these findings are visible with the naked eye, but they are there nonetheless.*

Gadolinium is neurotoxic.^{96,97,98,99} It has been found to inhibit mitochondrial function and induce oxidative stress.^{100,101} Brain bio-electric changes have been detected after IV administration of contrast.^{102,103} GBCA Product Labeling indicates that Gadolinium-Based Contrast Agents “do not cross an intact Blood-Brain Barrier”; however, “disruption of the Blood-Brain Barrier” (BBB) or “abnormal vascularity” allows *accumulation* in lesions such as neoplasms, abscesses, and subacute infarcts.^{104,105,106,107,108,109,110} There appear to be multiple ways that BBB permeability might be increased or temporarily altered including by MRI itself.^{111,112,113,114} Other ways the BBB might be crossed or altered include: the lack of a BBB on the Optic Nerve Head^{115,116} circumventricular organs (CVOs)¹¹⁷ and Choroid Plexuses,^{118,119} having Type II Diabetes or a white matter hypersensitivity like hypertension;¹²⁰ diffusion into the vitreous and aqueous humors of the ocular globes, perivascular spaces, and ventricles of the brain;¹²¹ diffusion into the subarachnoid^{122,123,124} or subdural spaces;¹²⁵ effects of Electromagnetic Pulse (EMP),^{126,127} Electromagnetic Fields (EMF),^{128,129} and RadioFrequency (RF) fields.¹³⁰ Findings of delayed and hyperintense enhancement of Cerebrospinal Fluid (CSF) have been reported in patients with *normal* renal

function.^{131,132,133,134,135} What long-term neurological effects might Gadolinium have on *all* patients when it crosses the Blood-Brain Barrier and/or deposits in brain tissue?

Is there really a logical reason to believe that all these things would happen only to those with severe renal problems? Or is it more likely that even those with normal renal function may have an ongoing fibrotic process that manifests in a chronic rather than an acute manner? It's estimated that approximately 1% or 15 mg of injected Gadolinium remains in the body^{136,137,138,139} from each standard dose – even in those with normal renal function. So what happens when patients have 5, 10, 15, 25 or even more MRIs with contrast such as might routinely happen to MS patients?^{140,141} Might that deposited Gadolinium explain reports of clinical worsening of MS symptoms after contrast MRIs?^{142,143} Could the brain atrophy associated with hyperintense MS plaques also be the result of deposited Gadolinium?^{144,145} And what happens to patients who receive more than the standard dose, especially the triple dose which is often administered for Off-Label use for an MRA?^{146,147} Does anyone really know?

I must say that I'm left wondering why the FDA has allowed GBCAs to still be administered now that it's known that 1% and perhaps even more of free Gadolinium, a toxic heavy metal, will remain in the patient's body.

A 1991 article entitled: “*Metal Ion Release from Paramagnetic Chelates: What is Tolerable?*”¹⁴⁸ found that “minute amounts of chelated or unchelated metals are likely to remain in the body for an extended period and could possibly result in a *toxic* effect.” The authors acknowledged that this could “result in *accumulation* of metal ion” and that the “*long-term effects of such potential deposition have yet to be determined*”. They also said it was “*unlikely that MRI contrast agents would be administered repeatedly in patients*”. Unfortunately, their assumption was incorrect and many patients do have multiple scans with contrast which results in even more remaining in the body. ***How much “accumulating metal ion” in the form of free Gadolinium can we tolerate? Have clinical studies been performed to make that determination?***

A 2007 study by Abraham et al found that “dermal inorganic Gadolinium concentrations increased over time in patients with multiple sequential biopsies” which was considered to suggest that “Gadolinium may be mobilized over time from bone stores” – “regardless of renal function at present”.¹⁴⁹ Based on what I've read this isn't surprising; since at least the early 1950s, Lanthanide Elements such as Gadolinium have been called “Bone Seekers”^{150,151} and more recent research confirms that free Gadolinium does deposit in bone.^{53,78,79} Gadolinium was found in hip bones taken from a patient with *normal* renal function as long as 8 years after the patient's last dose of contrast.¹³⁸ Dr. Henrik Thomsen of Denmark suggested that “long-term observations (e.g., 20 years) will be necessary before we can conclude anything about the safety of Gadolinium-Based Contrast Agents, in particular those with the lowest stability”.¹⁵² ***The long-term effects of deposited Gadolinium are still unknown and Cumulative Dose is considered by some researchers to pose a long-term risk for potentially everyone at some point in the future, including patients with normal renal function.***^{149,152,153,154,155,156,157,158}

While doing my research I came across a 2007 article written by J.F.M. Wetzels, Department of Nephrology, Radboud University Nijmegen Medical Centre, the Netherlands that really caused me to pause and think about the problems associated with Gadolinium-Based Contrast Agents. The title was “*Thorotrast toxicity: the safety of Gadolinium compounds*”.¹⁵⁹ Thorotrast was a radiocontrast agent used from 1930 to 1960. It wasn't until the late 1940's that the first “Thorotrast-related malignancies” were described. Thorotrast particles had been deposited in cells in the liver, spleen, bone marrow, and lymph nodes where they stayed and continually exposed the surrounding tissue to radiation. The problems created by Thorotrast had such a long-latency period that malignancies might not show up for 45 years or more later. Wetzels described what was happening with Gadolinium and NSF through 2006. He said that “Gadolinium is a heavy metal, is very toxic, and free Gadolinium causes severe hepatic necrosis. Therefore, the currently used Gadolinium-Based Contrast Agents are all chelates, which must ensure that no free Gadolinium is present in the circulation”. Wetzels closed by saying, “*we must keep in mind that toxic effects may occur less frequently, later, and only after repeated exposure in patients with less severe renal dysfunction*”. ***Like Wetzels, I also wonder if Gadolinium-Based Contrast Agents might be the next Thorotrast. Might they?***

These are very sobering thoughts to say the least. So what happens to the estimated “1%” of Gadolinium that was left behind after each MRI? And that “1%” assumes you had good kidney function, with no transient Acute Kidney Injury (AKI),^{160,161,162} you were not acidotic,¹⁶³ and you had none of the other risk factors known to cause more to remain in your body such as might happen during transmetallation.^{164,165,166,167,168,169} Other than impaired renal function, researchers have found that transmetallation presents the greatest potential risk for the release of the toxic metal ion from the chelate^{40,148} this can and has happened in those with normal renal function.^{23,24,170} Of note is the fact that GBCAs themselves have been found to be Nephrotoxic.^{171,172,173,174,175,176,177} On autopsies of NSF patients, Gadolinium and/or the fibrosis it caused have been found in many of the same areas where Thorotrast deposited, plus more.^{178,179,180} At what point will the Gadolinium someone received make its presence known - a month, a year, or 10 years from now? Or will patients spend their lives suffering from nagging, chronic health issues that no one can explain? And how much shorter might their lives be because of Gadolinium Toxicity or Gadolinium-Associated Systemic Fibrosis?

While some may be convinced that the potential benefits outweigh the risks, it doesn't appear to me that patients even know these risks exist. And yes, a tumor or lesion might be seen that may have otherwise been missed, but while it's being enhanced it's also being deposited with a toxic substance in the form of Gadolinium which is known to *accumulate* in abnormal tissue.¹⁵ A 2009 presentation made by Fulciniti et al, found that *Gadolinium Containing Contrast Agent Promotes Multiple Myeloma Cell Growth* and autopsies on 8 multiple myeloma patients also found “*massive quantities of Gadolinium accumulation in tissues regardless of their renal function*”.⁵⁵ A 2010 study by Xia et al found Gd-containing deposits in brain tumors following contrast-enhanced MRIs in patients *without* severe renal disease.⁵⁶ Since at least 1984 it has been known that Gadolinium (Gd-DTPA) “*does accumulate* at sites of blood-brain barrier disruption with obvious enhancement of central nervous system lesions including tumors and abscesses.”¹⁵ ***Since Gadolinium is known to be neurotoxic, what adverse effects might this accumulating Gadolinium have on all patients at some point in the future?***

Up until now, it appears that a determination as to whether or not a patient has been adversely affected by Gadolinium is being determined primarily by two things – renal impairment and presentation of skin changes in the patient consistent with the current diagnostic criteria for NSF. Is it possible that when varying amounts of Gadolinium remain in the patient's body for whatever reason, that it might result in different skin findings or possibly few if any visible skin changes at all? NSF has presented as a progressive myopathy with minimal skin findings and with osseous metaplasia.^{181,182,183,184} It's been reported that the skin manifestations in the late stages of NSF are different from those seen early in the disease and have a varied presentation.^{185,186} And a 2011 Japanese study suggested the occurrence of a non-plaque, late-onset type of NSF.¹⁸⁷ If less Gadolinium remains in the body, might there also be differences seen between renally-impaired and non-renally-impaired patients? Based on autopsy findings of NSF patients, isn't it also possible that the damage is being done on the *inside* of the patient and not readily seen with the naked eye regardless of the patient's level of renal function? While there appear to be many unanswered questions related to Gadolinium-Based Contrast Agents, what is known from the literature is that Gadolinium is toxic to humans and varying amounts of it have been detected in bone and tissue of patients - including in patients *without* severe renal disease.

In addition to the facts presented in my letter which are supported by numerous references from the published literature, I hope you will also consider the Personal Accounts of Suspected Gadolinium Toxicity that are enclosed. I believe they present a strong case that Gadolinium Toxicity does occur in patients with normal renal function in varying degrees and in a variety of ways that are consistent with what has been learned about the toxic effects of free Gadolinium from both animal testing and case studies and autopsy reviews of NSF patients. The patients whose Personal Accounts are enclosed, and the doctors treating them and others like them, need diagnostic criteria that will allow for further evaluation of the possible involvement of Gadolinium Toxicity or Gadolinium-Associated Systemic Fibrosis.

When you put all these pieces of information together, I believe it should be evident that Gadolinium-Based Contrast Agents pose a potentially serious health risk to everyone regardless of their level of renal function. Based on that fact, I believe the FDA should issue a “Safety Alert” regarding Cumulative Dose Risk from GBCAs in *all* patients. I also believe the FDA should initiate a Retrospective Study on Gadolinium Retention and its short and long-term effects on patients with normally functioning kidneys; to accurately determine the amount of

systemic involvement in the non-renal-impaired I believe this should also include autopsy reviews of patients having confirmed exposures to GBCAs and normal renal function.

Until such time as those studies can be completed, patients with normal renal function who are suffering from the toxic effects of Gadolinium need to be evaluated and properly diagnosed. While responsibility for these tasks might not fall directly under the FDA, I would hope that all government agencies and medical organizations would quickly come together to determine diagnostic criteria for Gadolinium Toxicity and/or Gadolinium-Associated Systemic Fibrosis (GASF). I know there is no cure for GASF at this time, but I firmly believe these patients (patients like me) deserve to know what it is they are facing so that they and their doctors can make more appropriate medical decisions related to their long-term care. Knowing the facts will allow these patients to avoid more unnecessary testing and the related medical expenses. But more importantly, it will allow them to go about living their lives as best they can rather than spending their days desperately seeking answers to their unexplained and unrelenting health issues.

While I understand that the FDA has guidelines to follow, I believe the already published scientific data related to Gadolinium-Based Contrast Agents and the toxic effects of free Gadolinium call into serious question the long-term safety of using these contrast agents in all patient populations. Based on the totality of the facts, I believe immediate action by the FDA is warranted.

I hope you will give this serious problem the consideration that a problem of this potential magnitude deserves. At the beginning I said this is "complicated", but really it shouldn't be. No amount of Gadolinium is truly safe to inject into humans, at least not without extensive further evaluation in all patients including those with normal renal function.

Thank you for taking the time to read my letter and supporting materials. I look forward to hearing from someone at the FDA about this matter. Please feel free to contact me by phone at home at [REDACTED]. My mailing address is: [REDACTED].

Thank you.

Sincerely,

Sharon Williams

Enclosures: Personal Accounts; Reference List

cc: Secretary Kathleen Sebelius, U.S. Department of Health & Human Services
Stephen P. Spielberg, MD, Deputy Commissioner for Medical Products and Tobacco (FDA)
Janet Woodstock, MD, Director, Center for Drug Evaluation and Research (FDA)
Gayatri R. Rao, MD, Director, Office of Orphan Products Development (FDA)
John Jenkins, MD, Director, Office of New Drugs (FDA)
Ira Krefting, MD, Deputy Director for Safety (CDER - FDA)
Regina M. Benjamin, MD, Surgeon General
Thomas R. Frieden, MD, MPH, Director, CDC
Francis S. Collins, MD, Director, NIH
Sen. Tom Harkin, Chairman, Senate Committee on Health, Education, Labor & Pensions
Rep. Fred Upton, Chairman, House Committee on Energy & Commerce

References

- ¹ Sherry AD, Caravan P, Lenkinski RE. Primer on gadolinium chemistry. *Journal of Magnetic Resonance Imaging : JMRI*. 2009;30(6):1240–8.
- ² Anon. Gadolinium Chloride Solution: AMERICAN ELEMENTS Supplier & Tech Info. Available at: <http://www.americanelements.com/gdclsol.html>. Accessed October 9, 2012.
- ³ HALEY TJ, RAYMOND K, KOMESU N, UPHAM HC. Toxicological and pharmacological effects of gadolinium and samarium chlorides. *British Journal of Pharmacology and Chemotherapy*. 1961;17:526–32.
- ⁴ Gabbiani G, Jacqmin ML, Richard RM. Soft-tissue calcification induced by rare earth metals and its prevention by sodium pyrophosphate. *British Journal of Pharmacology and Chemotherapy*. 1966;27(1):1–9.
- ⁵ Spencer AJ, Wilson SA, Batchelor J, et al. Gadolinium Chloride Toxicity in the Rat . *Toxicologic Pathology* .1997;25 (3):245–255.
- ⁶ Rees J, Spencer A, Wilson S, Reid A, Harpur E. Time Course of Stomach Mineralization, Plasma, and Urinary Changes After a Single Intravenous Administration of Gadolinium(III) Chloride in the Male Rat . *Toxicologic Pathology* . 1997;25 (6):582–589.
- ⁷ Adding LC, Bannenberg GL, Gustafsson LE. Basic Experimental Studies and Clinical Aspects of Gadolinium Salts and Chelates. *Cardiovascular Drug Reviews*. 2006;19(1):41–56.
- ⁸ Hirano S, Suzuki KT. Exposure, metabolism, and toxicity of rare earths and related compounds. *Environmental health perspectives*. 1996;104 Suppl :85–95.
- ⁹ Angeli JK, et al. Gadolinium increases the vascular reactivity of rat aortic rings. *Braz J Med Biol Res*. 2011;44:445–452.
- ¹⁰ Vassallo D, et al. Toxic effects of mercury, lead and gadolinium on vascular reactivity. *Braz J Med Biol Res*. 2011;44:939–946.
- ¹¹ Anon. Toxicology Excellence for Risk Assessment. *Development of Reference Doses and Reference Concentrations for Lanthanides for the Bureau of Land Management*. 1999.
- ¹² Husztki E, Lázár G, Párducz A. Electron microscopic study of Kupffer-cell phagocytosis blockade induced by gadolinium chloride. *British Journal of Experimental Pathology*. 1980;61(6):624–30.
- ¹³ Mizgerd J, et al. Gadolinium induces macrophage apoptosis. *Journal of Leukocyte Biology*. 1996;59(February):189–195.
- ¹⁴ Weinmann H-J, Brasch RC, Press W-R, Wesbey G. Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent. *AJR. American journal of roentgenology*. 1984;March(142):619–624.
- ¹⁵ Brasch RC. Inherent contrast in magnetic resonance imaging and the potential for contrast enhancement. The 1984 L. Henry Garland lecture. *The Western Journal of Medicine*. 1985;142(6):847–53.
- ¹⁶ Mann JS. Stability of gadolinium complexes in vitro and in vivo. *Journal of Computer Assisted Tomography*. 1993;17 Suppl 1:S19–23.
- ¹⁷ Carr D, et al. Gadolinium-DTPA as a Contrast Agent in MRI: Initial Clinical Experience in 20 patients. *AJR*. 1984;August(143):215–224.
- ¹⁸ Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. *Magnetic resonance imaging*. 1992;10(4):641–8.
- ¹⁹ Kasokat T, Urlich K. Quantification of dechelation of gadopentetate dimeglumine in rats. *Arzneimittel-Forschung*. 1992;42(6):869–76.
- ²⁰ Corot C, Idee JM, Hentsch AM, et al. Structure-activity relationship of macrocyclic and linear gadolinium chelates: investigation of transmetallation effect on the zinc-dependent metalloproteinase angiotensin-converting enzyme. *Journal of magnetic resonance imaging : JMRI*. 8(3):695–702.
- ²¹ Idée JM, Berthommier C, Goulas V, et al. Haemodynamic effects of macrocyclic and linear gadolinium chelates in rats: role of calcium and transmetallation. *Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine*. 1998;11(2):113–23.
- ²² Idée J-M, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. *Fundamental & Clinical Pharmacology*. 2006;20(6):563–76.
- ²³ Puttagunta NR, Gibby WA, Smith GT. Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. *Investigative Radiology*. 1996;31(12):739–42.
- ²⁴ Kimura J, Ishiguchi T, Matsuda J, et al. Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. *Radiation Medicine*. 2005;23(5):322–6.

References

- ²⁵ Frenzel T, Lengsfeld P, Schirmer H, Hütter J, Weinmann H-J. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. *Investigative Radiology*. 2008;43(12):817–28.
- ²⁶ Cowper SE, Robin HS, Steinberg SM, et al. Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. *Lancet*. 2000;356(9234):1000–1.
- ²⁷ Cowper SE, Su LD, Bhawan J, Robin HS, LeBoit PE. Nephrogenic fibrosing dermopathy. *The American Journal of Dermatopathology*. 2001;23(5):383–93.
- ²⁸ Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. *Archives of Dermatology*. 2003;139(7):903–6.
- ²⁹ Levine JM, Taylor RA, Elman LB, et al. Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). *Muscle & nerve*. 2004;30(5):569–77.
- ³⁰ Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. *American Journal of Kidney Diseases : the official journal of the National Kidney Foundation*. 2005;46(4):754–9.
- ³¹ Cowper SE, Boyer PJ. Nephrogenic systemic fibrosis: an update. *Current rheumatology reports*. 2006;8(2):151–7.
- ³² Grobner T. Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? *Nephrology, dialysis, transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association*. 2006;21(4):1104–8.
- ³³ Marckmann P, Skov L, Rossen K, et al. Nephrogenic Systemic Fibrosis: Suspected Causative Role of Gadodiamide Used for Contrast-Enhanced Magnetic Resonance Imaging. *J Am Soc Nephrol*. 2006;17:2359–2362.
- ³⁴ Kribben A, Witzke O, Hillen U, et al. Nephrogenic systemic fibrosis: pathogenesis, diagnosis, and therapy. *Journal of the American College of Cardiology*. 2009;53(18):1621–8.
- ³⁵ Anon. Roentgen Ray Reader: New Proposed Criteria for Diagnosis of Nephrogenic Systemic Fibrosis. Available at: http://roentgenrayreader.blogspot.com/2011/10/new-proposed-criteria-for-diagnosis-of_14.html.
- ³⁶ Sieber MA, Pietsch H, Walter J, et al. A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media. *Investigative Radiology*. 2008;43(1).
- ³⁷ Sieber MA, Lengsfeld P, Frenzel T, et al. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. *European Radiology*. 2008;18(10):2164–73.
- ³⁸ Haylor J, Dencausse A, Vickers M, et al. Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. *Investigative Radiology*. 2010;45(9):507–12.
- ³⁹ Pietsch H, Pering C, Lengsfeld P, et al. Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. *Journal of magnetic resonance imaging : JMRI*. 2009;30(2):374–83.
- ⁴⁰ Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. *Magnetic Resonance Imaging*. 1990;8(4):467–481.
- ⁴¹ Altun E, Martin DR, Wertman R, et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities. *Radiology*. 2009;253(3):689–96.
- ⁴² Martin DR, Krishnamoorthy SK, Kalb B, et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. *Journal of Magnetic Resonance Imaging : JMRI*. 2010;31(2):440–6.
- ⁴³ Kim K-H, Fonda JR, Lawler EV, Gagnon D, Kaufman JS. Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008. *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 2010;56(3):458–67.
- ⁴⁴ U.S. Food & Drug Administration. Postmarket Drug Safety Information for Patients and Providers - Information for Healthcare Professionals: Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, Optimark, ProHance). UCM142884. 2007. Available at: <http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm142884.htm>.
- ⁴⁵ U.S. Food & Drug Administration. Press Announcements - FDA: New warnings required on use of gadolinium-based contrast agents. UCM225286. 2010. Available at: <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225286.htm>.
- ⁴⁶ Center for Drug Evaluation and Research. Drug Safety and Availability - FDA Drug Safety Communication: New warnings for using gadolinium-based contrast agents in patients with kidney dysfunction. UCM223966. 2010. Available at: <http://www.fda.gov/drugs/drugsafety/ucm223966.htm>.

References

-
- ⁴⁷ Food and Drug Administration. Establish a Patient-Based Registry To Evaluate the Association of Gadolinium Based Contrast Agents Exposure and Nephrogenic Systemic Fibrosis (2012-17454). 2012. Available at: <http://www.gpo.gov/fdsys/pkg/FR-2012-07-18/pdf/2012-17454.pdf>.
- ⁴⁸ Tweedle MF. Physicochemical Properties of Gadoteridol and Other Magnetic Resonance Contrast Agents. *Investigative Radiology*. 1992;2–6. Available at: http://www.ph.braccosolutions.com/Shared Documents/Tweedle Physicochemical_Properties_of_Gadoteridol_and.2.pdf.
- ⁴⁹ Harpur ES, et. Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast Agent. *Investigative Radiology*. 1993;28(Supplement 1):S28–S43.
- ⁵⁰ Pietsch H, Lengsfeld P, Jost G, et al. Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. *European Radiology*. 2009;19(6):1417–24.
- ⁵¹ Grant D, Johnsen H, Juelsrud A, Løyhaug D. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. *Acta radiologica (Stockholm, Sweden : 1987)*. 2009;50(2):156–69.
- ⁵² Pietsch H, Raschke M, Ellinger-Ziegelbauer H, et al. The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. *Investigative Radiology*. 2011;46(1):48–56.
- ⁵³ Kindberg GM, Uran S, Friisk G, Martinsen I, Skotland T. The fate of Gd and chelate following intravenous injection of gadodiamide in rats. *European radiology*. 2010;20(7):1636–43.
- ⁵⁴ Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. *Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine*. 2010;64(5):1274–80.
- ⁵⁵ Fulciniti M, et al, Dana Farber Cancer Institute Harvard Medical School. *Gadolinium Containig Contrast Agent Promotes Multiple Myeloma Cell Growth: Implications for Clinical Use of MRI in Myeloma (poster presentation)*. 2009.
- ⁵⁶ Xia D, Davis RL, Crawford JA, Abraham JL. Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. *Acta Radiologica (Stockholm, Sweden : 1987)*. 2010;51(10):1126–36.
- ⁵⁷ Kay J, Czirjak L. Gadolinium and systemic fibrosis: guilt by association. *Annals of the Rheumatic Diseases*. 2010;69(11):1895–1897.
- ⁵⁸ Kay J. Gadolinium and Nephrogenic Systemic Fibrosis: The evidence of things not seen. (editorial). *Cleveland Clinic Journal of Medicine*. 2008;75(2):112–117.
- ⁵⁹ Bhagavathula N, Dame MK, DaSilva M, et al. Fibroblast response to Gadolinium: role for platelet-derived growth factor receptor. *Investigative Radiology*. 2010;45(12):769–77.
- ⁶⁰ DaSilva M, O'Brien Deming M, Fligel SEG, et al. Responses of human skin in organ culture and human skin fibroblasts to a Gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. *Investigative Radiology*. 2010;45(11):733–9.
- ⁶¹ Piera-Velazquez S, Louneva N, Fertala J, et al. Persistent activation of dermal fibroblasts from patients with Gadolinium-associated nephrogenic systemic fibrosis. *Annals of the Rheumatic Diseases*. 2010;69(11):2017–23.
- ⁶² Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. Effect of different classes of Gadolinium-Based Contrast Agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. *Radiology*. 2010;256(3):735–43.
- ⁶³ Aime S, Caravan P. Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. *Journal of Magnetic Resonance Imaging*. 2009;30(6):1259–1267.
- ⁶⁴ Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. *Investigative Radiology*. 1995;30(6):372–80.
- ⁶⁵ Elmholt TR, Jorgensen B, Ramsing M, Pedersen M, Olesen AB. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. *NDT Plus*. 2010;3(3):285–287.
- ⁶⁶ Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. NFκB activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. *Annals of the Rheumatic Diseases*. 2010;69(11):2024–33.
- ⁶⁷ Varani J, DaSilva M, Warner RL, et al. Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. *Investigative radiology*. 2009;44(2):74–81.
- ⁶⁸ Edward M, Quinn JA, Mukherjee S, et al. Gadodiamide contrast agent “activates” fibroblasts: a possible cause of nephrogenic systemic fibrosis. *The Journal of Pathology*. 2008;214(5):584–93.

References

- ⁶⁹ Wermuth PJ, Del Galdo F, Jiménez SA. Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. *Arthritis and Rheumatism*. 2009;60(5):1508–18
- ⁷⁰ FDA Advisory Committees. Gadolinium-Based Contrast Agents & Nephrogenic Systemic Fibrosis - FDA Briefing Document - Advisory Committee December 8, 2009. (UCM190850.pdf). 2009. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM190850.pdf>.
- ⁷¹ FDA Advisory Committees. Gadolinium-based Contrast Agents (GBCA) & Nephrogenic Systemic Fibrosis - Joint Meeting Drug Safety and Risk Mgmt. Advisory Cmtes. - December 8, 2009. UCM196218.pdf. 2009. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196218.pdf>.
- ⁷² GE Healthcare. Omniscan Advisory Meeting Briefing Document - November 3, 2009 - Version 1. (UCM192009.pdf). 2009:1–108. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM192009.pdf>.
- ⁷³ Bayer HealthCare Pharmaceuticals. Magnevist. Sponsors Background Package for FDA Advisory Committee Meeting - December 8, 2009. UCM192006.pdf. 2009:1–120. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM192006.pdf>.
- ⁷⁴ Bracco Diagnostics Inc. MultiHance FDA Advisory Committee Briefing Materials October 30, 2009 (UCM192007.pdf). 2009. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM192007.pdf>.
- ⁷⁵ Bracco Diagnostics Inc. ProHance FDA Briefing Document. Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. December 9, 2009. UCM196224.pdf. 2009. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196224.pdf>.
- ⁷⁶ Bracco Diagnostics Inc. Joint Meeting of Drug Safety and Risk Management Advisory Committee December 8, 2009 - MultiHance. UCM196225. 2009. Available at: <http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/cardiovascularandrenaldrugsadvisorycommittee/ucm196225.pdf>.
- ⁷⁷ Covidien. Optimark. FDA Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committees. December 8, 2009. UCM196229.pdf. 2009. Available at: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM196229.pdf>.
- ⁷⁸ Gibby WA, Gibby KA, Gibby WA. Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. *Investigative Radiology*. 2004;39(3):138–42.
- ⁷⁹ White GW, Gibby WA, Tweedle MF. Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. *Investigative Radiology*. 2006;41(3):272–8.
- ⁸⁰ Girardi M, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. *Journal of the American Academy of Dermatology*. 2011;65(6):1095–1106.e7.
- ⁸¹ Basak P, Jesmajian S. Nephrogenic systemic fibrosis: current concepts. *Indian journal of dermatology*. 2011;56(1):59–64.
- ⁸² Sanyal S, Marckmann P, Scherer S, Abraham J. Multiorgan Gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis - an autopsy-based review. *Nephrology Dialysis Transplant*. 2011;(0):1–11.
- ⁸³ Ting WW, Stone MS, Madison KC, Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. *Archives of Dermatology*. 2003;139(7):903–6.
- ⁸⁴ Aggarwal A, Froehlich AA, Essah P, et al. Complications of nephrogenic systemic fibrosis following repeated exposure to Gadolinium in a man with hypothyroidism: a case report. *Journal of Medical Case Reports*. 2011;5:566.
- ⁸⁵ Gibson S, Farver C, Prayson R. Multiorgan Involvement in Nephrogenic Fibrosing Dermopathy An Autopsy Case and Review of the Literature. Gibson SE, Farver CF, Prayson RA. *Arch Pathol Lab Med*. 2006;130:209–212. *Arch Pathol Lab Med*. 2006;(130):209–212.

References

- ⁸⁶ Daram SR, Cortese CM, Bastani B. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. *American Journal of Kidney Diseases : the official journal of the National Kidney Foundation*. 2005;46(4):754–9.
- ⁸⁷ Krous HF, Breisch E, Chadwick AE, et al. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing's sarcoma, end-stage renal disease, and hemodialysis. *Pediatric and Developmental Pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society*. 2007;10(5):395–402.
- ⁸⁸ Kucher C, Steere J, Elenitsas R, Siegel DL, Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. *Journal of the American Academy of Dermatology*. 2006;54(2 Suppl):S31–4.
- ⁸⁹ Swaminathan S, High WA, Ranville J, et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. *Kidney International*. 2008;73(12):1413–8.
- ⁹⁰ Koreishi A, et al. Nephrogenic Systemic Fibrosis A Pathologic Study of Autopsy Cases. *Arch Pathol Lab Med*. 2009;133(December):1943–1948.
- ⁹¹ Gibson S, Farver C, Prayson R. Multiorgan Involvement in Nephrogenic Fibrosing Dermopathy An Autopsy Case and Review of the Literature. Gibson SE, Farver CF, Prayson RA. *Arch Pathol Lab Med*. 2006;130:209–212. *Arch Pathol Lab Med*. 2006;(130):209–212.
- ⁹² Saenz A, Mandal R, Kradin R, Hedley-Whyte ET. Nephrogenic fibrosing dermopathy with involvement of the dura mater. *Virchows Archiv : an international journal of pathology*. 2006;449(3):389–91.
- ⁹³ Perez-Rodriguez J, Lai S, Eht BD, Fine DM, Bluemke DA. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment--report of 33 cases. *Radiology*. 2009;250(2):371–7.
- ⁹⁴ Barker-Griffith A, Goldberg J, Abraham JL. Ocular pathologic features and Gadolinium deposition in nephrogenic systemic fibrosis. *Archives of Ophthalmology*. 2011;129(5):661–3.
- ⁹⁵ Jornet AR et al. Revista Nefrologia - Gadolinium-induced systemic fibrosis in severe renal failure. *Revista Nefrologia*. 2009. Available at: http://www.revistanefrologia.com/modules.php?name=articulos&d_op=&idarticulo=129&idlangart=EN&preproduccion=.
- ⁹⁶ Ray DE, et al. Neurotoxic Effects of Gadopentetate Dimeglumine: Behavioral Disturbance and Morphology after Intracerebroventricular Injection in Rats. *AJNR. American Journal of Neuroradiology*. 1996;February(17):365–373.
- ⁹⁷ Ray DE, Holton JL, Nolan CC, Cavanagh JB, Harpur ES. Neurotoxic potential of gadodiamide after injection into the lateral cerebral ventricle of rats. *American Journal of Neuroradiology*. 1998;19 (8):1455–1462.
- ⁹⁸ Roman-Goldstein SM, Barnett PA, McCormick CI, et al. Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: toxicity and MR imaging findings. *AJNR. American Journal of Neuroradiology*. 1991;12(5):885–90.
- ⁹⁹ Feng X-D, Xia Q, Yuan L, et al. Gadolinium triggers unfolded protein responses (UPRs) in primary cultured rat cortical astrocytes via promotion of an influx of extracellular Ca²⁺. *Cell biology and toxicology*. 2011;27(1):1–12.
- ¹⁰⁰ Feng X, Xia Q, Yuan L, Yang X, Wang K. Impaired mitochondrial function and oxidative stress in rat cortical neurons: implications for gadolinium-induced neurotoxicity. *Neurotoxicology*. 2010;31(4):391–8.
- ¹⁰¹ Xia Q, Feng X, Huang H, et al. Gadolinium-induced oxidative stress triggers endoplasmic reticulum stress in rat cortical neurons. *Journal of neurochemistry*. 2011;117(1):38–47.
- ¹⁰² Messori A, Polonara G, Regnicolo L, et al. Effects of ionic and non-ionic paramagnetic contrast media on brain bio-electric activity. *Neuroradiology*. 2005;47(11):820–5.
- ¹⁰³ Salvolini U, Provinciali L, Signorino M. Letter: Functional Effects of Contrast Media on the Brain. *AJNR*. 2001;(January):228.
- ¹⁰⁴ Bayer HealthCare Pharmaceuticals. Magnevist Package Insert.pdf. 2012. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Magnevist_PI.pdf.
- ¹⁰⁵ GE Healthcare. OMNISCAN Product Labeling. December 2010. (020123s0371bl.pdf). 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020123s0371bl.pdf.
- ¹⁰⁶ Mallinckrodt Inc. Optimark Product Labeling 2010. (020937s0161bl.pdf). 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020937s0161bl.pdf.
- ¹⁰⁷ Bracco Diagnostics Inc. ProHance Product Labeling 2010. (020131s0241bl.pdf). 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020131s0241bl.pdf.
- ¹⁰⁸ Bracco Diagnostics Inc. MultiHance Product Labeling 2012. 021357s0111bl.pdf. 2012. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/021357s0111bl.pdf.

References

-
- ¹⁰⁹ Lantheus Medical Imaging. ABLAVAR Product Labeling 2010. (021711s003lbl.pdf). 2010. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021711s003lbl.pdf.
- ¹¹⁰ Bayer HealthCare Pharmaceuticals. EOVIST Product Labeling 2011 (2011022090s005lbl.pdf). 2011. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022090s005lbl.pdf.
- ¹¹¹ Prato FS, Frappier JR, Shivers RR, et al. Magnetic resonance imaging increases the blood-brain barrier permeability to 153-Gadolinium diethylenetriaminepentaacetic acid in rats. *Brain Research*. 1990;523(2):301–4.
- ¹¹² Shivers RR, Kavaliers M, Teskey GC, Prato FS, Pelletier RM. Magnetic resonance imaging temporarily alters blood-brain barrier permeability in the rat. *Neuroscience Letters*. 1987;76(1):25–31.
- ¹¹³ Prato FS, Wills JM, Roger J, et al. Blood-brain barrier permeability in rats is altered by exposure to magnetic fields associated with magnetic resonance imaging at 1.5 T. *Microscopy Research and Technique*. 1994;27(6):528–34.
- ¹¹⁴ Lossinsky A, Shivers R. Structural pathways for macromolecular and cellular transport across the blood-brain barrier during inflammatory conditions. Review. *Histol Histopathol*. 2004;19:535–564.
- ¹¹⁵ Tso MOM, Shih C-Y, McLean IW. Is There a Blood-Brain Barrier at the Optic Nerve Head? *Archives of Ophthalmology*. 1975;93(9):815–825.
- ¹¹⁶ Hofman P, Hoyng P, vanderWerf F, Vrensen GFJM, Schlingemann RO. Lack of Blood-Brain Barrier Properties in Microvessels of the Prelaminar Optic Nerve Head. *Invest. Ophthalmol. Vis. Sci*. 2001;42(5):895–901.
- ¹¹⁷ Maaloud N, Meister B. Protein components of the blood-brain barrier (BBB) in the brainstem area postrema-nucleus tractus solitarius region. *Journal of chemical neuroanatomy*. 2009;37(3):182–95.
- ¹¹⁸ Yokel R. Blood-brain barrier flux of aluminum, manganese, iron and other metals suspected to contribute to metal-induced neurodegeneration. *Journal of Alzheimer's Disease*. 2006;10:223–253.
- ¹¹⁹ Engelhardt B, Wolburg-Buchholz K, Wolburg H. Involvement of the choroid plexus in central nervous system inflammation. *Microscopy research and technique*. 2001;52(1):112–29.
- ¹²⁰ Starr JM, Wardlaw J, Ferguson K, et al. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. *Journal of Neurology, Neurosurgery, and Psychiatry*. 2003;74(1):70–6.
- ¹²¹ Kanamalla US, Boyko OB. Gadolinium Diffusion into Orbital Vitreous and Aqueous Humor, Perivascular Space, and Ventricles in Patients with Chronic Renal Disease. *American Journal of Roentgenology*. 2002;179 (5):1350–1352.
- ¹²² Boyko OB, Kanamalla US, Memisoglu E, Kochan J, Schulman G. *Flair Imaging of Gadolinium Diffusion into Brain CSF and Vitreous of the Globe in Patients with Renal Disease: Proton MRS and DWI Correlation*. 2001.
- ¹²³ Morris JM, Miller GM. Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. *AJNR. American journal of neuroradiology*. 2007;28(10):1964–7.
- ¹²⁴ Mamourian AC, Jack Hoopes P, Lewis LD. Visualization of Intravenously Administered Contrast Material in the CSF on Fluid-Attenuated Inversion-Recovery MR Images: An In Vitro and Animal-Model Investigation. *AJNR Am. J. Neuroradiol*. 2000;21(1):105–111.
- ¹²⁵ Kanamalla US, Baker KB, Boyko OB. Gadolinium Diffusion into Subdural Space. *American Journal of Roentgenology*. 2001;176 (6):1604–1605.
- ¹²⁶ Ding G-R, Qiu L-B, Wang X-W, et al. EMP-induced alterations of tight junction protein expression and disruption of the blood-brain barrier. *Toxicology letters*. 2010;196(3):154–60.
- ¹²⁷ Qiu L, Ding G, Zhang Y, et al. Effects of electromagnetic pulse on blood-brain barrier permeability and tight junction proteins in rats. *Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases*. 2009;27(9):539–43.
- ¹²⁸ Salford LG, Nittby H, Brun A, et al. The Mammalian Brain in the Electromagnetic Fields Designed by Man with Special Reference to Blood-Brain Barrier Function, Neuronal Damage and Possible Physical Mechanisms. *Progress of Theoretical Physics Supplement*. 2008;173(173):283–309.
- ¹²⁹ Nittby H, Brun A, Eberhardt J, et al. Increased blood-brain barrier permeability in mammalian brain 7 days after exposure to the radiation from a GSM-900 mobile phone. *Pathophysiology : the official journal of the International Society for Pathophysiology / ISP*. 2009;16(2-3):103–12.
- ¹³⁰ Nittby H, Grafström G, Eberhardt JL, et al. Radiofrequency and extremely low-frequency electromagnetic field effects on the blood-brain barrier. *Electromagnetic biology and medicine*. 2008;27(2):103–26.

References

- ¹³¹ Naul LG, Finkenstaedt M. Extensive cerebrospinal fluid enhancement with gadopentetate dimeglumine in a primitive neuroectodermal tumor. *American Journal of Neuroradiology*. 1997;18 (9):1709–1711
- ¹³² Hamilton BE, Nesbit GM. Delayed CSF enhancement in posterior reversible encephalopathy syndrome. *AJNR. American journal of neuroradiology*. 2008;29(3):456–7.
- ¹³³ Mamourian AC, Jack Hoopes P, Lewis LD. Visualization of Intravenously Administered Contrast Material in the CSF on Fluid-Attenuated Inversion-Recovery MR Images: An In Vitro and Animal-Model Investigation. *AJNR Am. J. Neuroradiol*. 2000;21(1):105–111.
- ¹³⁴ Morris JM, Miller GM. Increased signal in the subarachnoid space on fluid-attenuated inversion recovery imaging associated with the clearance dynamics of gadolinium chelate: a potential diagnostic pitfall. *AJNR. American journal of neuroradiology*. 2007;28(10):1964–7.
- ¹³⁵ Levy LM. Exceeding the limits of the normal blood-brain barrier: quo vadis gadolinium? *AJNR. American journal of neuroradiology*. 2007;28(10):1835–6.
- ¹³⁶ Abraham JL. Author Interview Jerrold L. Abraham, MD - Multiorgan Gadolinium Deposition and Fibrosis in a patient with Nephrogenic Systemic Fibrosis - an autopsy-based review. *Hemodialysis.com*. 2011. Available at: http://www.hemodialysis.com/author_interview_gd_deposition_in_pt_with_nsf.html.
- ¹³⁷ Anon. Case 10 | Particle Analysis | SUNY Upstate Medical University. Available at: <http://www.upstate.edu/pathenvi/studies/cases/case10.php>. Accessed September 30, 2012.
- ¹³⁸ Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, et al. Incorporation of excess gadolinium into human bone from medical contrast agents. *Metallomics : integrated biometal science*. 2009;1(6):479–88.
- ¹³⁹ Weinmann H-J, Brasch RC, Press W-R, Wesbey G. Characteristics of Gadolinium-DTPA Complex: A Potential NMR Contrast Agent. *AJR. American journal of roentgenology*. 1984;March(142):619–624.
- ¹⁴⁰ Lövblad K-O, Anzalone N, Dörfler A, et al. MR imaging in multiple sclerosis: review and recommendations for current practice. *AJNR. American journal of neuroradiology*. 2010;31(6):983–9.
- ¹⁴¹ Simon JH, Li D, Traboulsee A, et al. Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines. *AJNR Am. J. Neuroradiol*. 2006;27(2):455–461.
- ¹⁴² Smith ME, Stone LA, Albert PS, et al. Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. *Annals of Neurology*. 1993;33(5):480–9.
- ¹⁴³ Fulgenzi A, et al. A case of multiple sclerosis improvement following removal of heavy metal intoxication. *Biometals*. 2012. Available at: [http://www.eurodream.net/files/A case of multiple sclerosis improvement following removal of heavy metal intoxication.pdf](http://www.eurodream.net/files/A%20case%20of%20multiple%20sclerosis%20improvement%20following%20removal%20of%20heavy%20metal%20intoxication.pdf). Accessed October 10, 2012.
- ¹⁴⁴ Simon JH. From enhancing lesions to brain atrophy in relapsing MS. *Journal of neuroimmunology*. 1999;98(1):7–15.
- ¹⁴⁵ Janardhan V, Suri S, Bakshi R. Multiple sclerosis: hyperintense lesions in the brain on nonenhanced T1-weighted MR images evidenced as areas of T1 shortening. *Radiology*. 2007;244(3):823–31.
- ¹⁴⁶ Nacif MS, Arai AE, Lima JAC, Bluemke DA. Gadolinium-enhanced cardiovascular magnetic resonance: administered dose in relationship to United States Food and Drug Administration (FDA) guidelines. *Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance*. 2012;14:18.
- ¹⁴⁷ Lin K. Administration of gadolinium-based contrast agents in MR angiography. *AJR. American journal of roentgenology*. 2009;192(4):W193; author reply W194.
- ¹⁴⁸ Rocklage SM, Worah D, Kim S-H. Metal ion release from paramagnetic chelates: What is tolerable? *Magnetic Resonance in Medicine*. 1991;22(2):216–221.
- ¹⁴⁹ Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. *The British Journal of Dermatology*. 2008;158(2):273–80.
- ¹⁵⁰ MacDonald NS, et al. The Skeletal Deposition of Yttrium. *Journal of Biological Chemistry*. 1951.
- ¹⁵¹ Johannsson O, Perrault G, Savoie L, Tuchweber B. Action of various metallic chlorides on calcaemia and phosphataemia. *British Journal of Pharmacology and Chemotherapy*. 1968;33(1):91–7.
- ¹⁵² Thomsen HS. Is NSF only the tip of the “gadolinium toxicity” iceberg? *Journal of Magnetic Resonance Imaging : JMRI*. 2008;28(2):284–6.

References

-
- ¹⁵³ Thakral C, Alhariri J, Abraham JL. Long-term retention of gadolinium in tissues from nephrogenic systemic fibrosis patient after multiple gadolinium-enhanced MRI scans: case report and implications. *Contrast Media & Molecular Imaging*. 2007;2(4):199–205.
- ¹⁵⁴ Abraham JL, Thakral C. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis. *European Journal of Radiology*. 2008;66(2):200–7.
- ¹⁵⁵ Thakral C, Abraham JL. Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. *Journal of Cutaneous Pathology*. 2009;36(12):1244–54.
- ¹⁵⁶ Morcos SK, Haylor J. Pathophysiology of nephrogenic systemic fibrosis: A review of experimental data. *World Journal of Radiology*. 2010;2(11):427–33.
- ¹⁵⁷ European Medicines Agency Priorities for Drug Safety Research. Gadolinium-containing contrast agents and nephrogenic systemic fibrosis: Long-term consequences of retention in human skin and bone. 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2010/07/WC500094268.pdf. Accessed October 8, 2012.
- ¹⁵⁸ European Medicines Agency. Assessment report for Gadolinium-containing contrast agents. 1 July 2010. EMA/740640/2010. 2010. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/gadolinium_31/WC500099538.pdf.
- ¹⁵⁹ Wetzels JFM. Thorotrast toxicity: the safety of gadolinium compounds. *The Netherlands Journal of Medicine*. 2007;65(8):276–278.
- ¹⁶⁰ Cantor E. Identifying Acute Kidney Injury in High-risk Patients08. *A GE Healthcare MR publication*. 2008:71–72.
- ¹⁶¹ Soni SS, Ronco C, Katz N, Cruz DN. Early diagnosis of acute kidney injury: the promise of novel biomarkers. *Blood purification*. 2009;28(3):165–74.
- ¹⁶² Lewington A, Kanagasundarem S. CLINICAL PRACTICE GUIDELINES ACUTE KIDNEY INJURY UK Renal Association Dr Andrew Lewington & Dr Suren Kanagasundaram Posted at www.renal.org/guidelines. 2011;(August 2010). Available at: http://www.renal.org/Libraries/Guidelines/Acute_Kidney_Injury_-_Final_Version_08_March_2011.sflb.ashx.
- ¹⁶³ McNaughton C. Metabolic Acidosis.pdf. 2004:1–2. Available at: http://www.dreddyclinic.com/online_recources/pH/Metabolic_Acidosis.pdf. Accessed October 14, 2012.
- ¹⁶⁴ Rofsky NM, Sherry AD, Lenkinski RE. Nephrogenic systemic fibrosis: a chemical perspective. *Radiology*. 2008;247(3):608–12.
- ¹⁶⁵ Vorobiov M, Basok A, Tovbin D, et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. *Nephrology Dialysis Transplantation*. 2003;18(5):884–887.
- ¹⁶⁶ Sadowski EA, Bennett LK, Chan MR, et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. *Radiology*. 2007;243(1):148–57.
- ¹⁶⁷ Prince MR, Zhang H, Morris M, et al. Incidence of Nephrogenic Systemic Fibrosis at Two Large Medical Centers1. *Radiology*. 2008;248(3):807–816.
- ¹⁶⁸ Hope TA, High WA, Leboit PE, et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. *Radiology*. 2009;253(2):390–8.
- ¹⁶⁹ Idée J-M, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. *Fundamental & Clinical Pharmacology*. 2006;20(6):563–76.
- ¹⁷⁰ Greenberg SA. Zinc transmetallation and gadolinium retention after MR imaging: case report. *Radiology*. 2010;257(3):670–3.
- ¹⁷¹ Akgun H, Gonlusen G, Cartwright Jr. J, Suki W, Truong LD. Are Gadolinium-Based Contrast Media Nephrotoxic? A Renal Biopsy Study. *Arch Pathol Lab Med*. 2006;130(September).
- ¹⁷² Elmståhl B, Nyman U, Leander P, et al. Gadolinium contrast media are more nephrotoxic than iodine media. The importance of osmolality in direct renal artery injections. *European Radiology*. 2006;16(12):2712–20.
- ¹⁷³ Thomsen HS, et al. Gadolinium-containing Contrast Media for Radiographic Examinations: A Position Paper. *European radiology*. 2002;12:2600–2605.
- ¹⁷⁴ Heinrich MC, Kuhlmann MK, Kohlbacher S, et al. Cytotoxicity of iodinated and gadolinium-based contrast agents in renal tubular cells at angiographic concentrations: in vitro study. *Radiology*. 2007;242(2):425–34.
- ¹⁷⁵ Ledneva E, Karie S, Launay-Vacher V, Janus N, Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. *Radiology*. 2009;250(3):618–28.
- ¹⁷⁶ Nyman U, Elmstahl B, Leander P, et al. Are Gadolinium-based Contrast Media Really Safer than Iodinated Media for Digital Subtraction Angiography in Patients with Azotemia? *Radiology*. 2002;223(2):311–318.

References

-
- ¹⁷⁷ Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. *Clinical Journal of the American Society of Nephrology : CJASN*. 2009;4(2):461–9.
- ¹⁷⁸ Boyd J, Langlands A, MacCabe J. Long-Term Hazards of Thorotrast. *The British Medical Journal*. 1968;2(5604):517–521.
- ¹⁷⁹ Vuyst PD, et al. Lung fibrosis induced by Thorotrast. *Thorax*. 1990;45:899–901.
- ¹⁸⁰ Jennings RC, Priestley SE. Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral Thorotrast administration. *J Clin Pathol*. 1978;1125–1132. Available at: <http://jcp.bmj.com/content/31/12/1125.full.pdf>. Accessed October 9, 2012.
- ¹⁸¹ Edgar E, Woltjer R, Whitham R, et al. Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation. *Neuromuscular Disorders : NMD*. 2010;20(6):411–3.
- ¹⁸² Nagai Y, et al. Nephrogenic Systemic Fibrosis with Multiple Calcification and Osseous Metaplasia. *Acta Dermato-Venereologica*. 2008;88:597–600.
- ¹⁸³ Berk D, et al. Osseous metaplasia late in the course of nephrogenic systemic fibrosis. *Dermatology Online Journal*. 2010;16(8).
- ¹⁸⁴ Wiedemeyer K, Kutzner H, Abraham JL, et al. The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. *The American Journal of dermatopathology*. 2009;31(7):674–81.
- ¹⁸⁵ Bangsgaard N, Marckmann P, Rossen K, Skov L. Nephrogenic systemic fibrosis: late skin manifestations. *Archives of Dermatology*. 2009;145(2):183–7.
- ¹⁸⁶ Boyd AS, Zic JA, Abraham JL. Gadolinium deposition in nephrogenic fibrosing dermopathy. *J Am Acad Dermatol*. 2006:1–4. Available at: http://www.pkdiet.com/pdf/Img_gadolinium_NFD.pdf. Accessed September 15, 2012.
- ¹⁸⁷ Matsumoto Y, Mitsunashi Y, Monma F, et al. Nephrogenic systemic fibrosis: a case report and review on Japanese patients. *The Journal of dermatology*. 2012;39(5):449–53.